Predictive Biology is a research stage company structured aroud identifying novel pathways/targets for drug discovery purposes: developing novel stem cell technologies designed to enable the uncovering the genetic basis of variable drug response. Principals of the firm conduct genetic screens using 3D in vitro models produced from genetically diverse mouse and human stem cell lines. Current CNS projects use cerebral organoids and single cell RNAseq to investigate antidepressant mechanisms of action, identify modifiers of cytotoxic edema and understand population response to environmental neurotoxicants. Predictive Biology Inc is also exploring aspects of population genetics to bring to light causal variants of disease. The organizing principle is to identify novel pathways/targets for drug discovery purposes. Predictive Biology brings together stem cell biology, high throughput screening and genetics to elucidate molecular mechanisms underlying compound response. The firm uses their proprietary in vitro genetics platform in collaboration with drug industry partners to identify novel drug targets and elucidate molecular mechanisms of action. Collaborations with government partners involve determining pathways of toxicity for hundreds to thousands of environmental toxicants.
